Ginkgo Bioworks and the Government of the Republic of Panama Announce Plans to Establish New Biosecurity Capabilities
- Ginkgo Bioworks and the Gorgas Institute's collaboration is a significant step towards strengthening biosecurity capabilities in Latin America, with a focus on pathogen detection and monitoring. The strategic locations for surveillance, including urban centers and ports-of-entry, demonstrate a comprehensive approach to enhancing public health and national security in Panama. The partnership's aim to contribute to regional pandemic preparedness highlights the broader impact of this initiative.
- None.
Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it builds
As part of the program, Concentric will collaborate with the Gorgas Institute to strengthen their current surveillance infrastructure for COVID-19, as well as other respiratory and enteric pathogens, leveraging Concentric's expertise in wastewater monitoring, lab enablement, and bioinformatics analysis and decision support.
The program is expected to operate in strategic locations that can help bolster both national and regional public health and security throughout
By establishing these monitoring programs,
"We're honored to collaborate with the
"These detection and monitoring programs are an important aspect of
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.
About the Gorgas Memorial Institute for Health Studies
Gorgas Memorial Institute is the national reference laboratory and research institute of
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's biosecurity platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the
GINKGO MEDIA CONTACT:
press@ginkgobioworks.com
GINKGO INVESTOR CONTACT:
investors@ginkgobioworks.com
mebantinori@gorgas.gob.pa
jmpascale@gorgas.gob.pa
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-the-government-of-the-republic-of-panama-announce-plans-to-establish-new-biosecurity-capabilities-301892164.html
SOURCE Ginkgo Bioworks
FAQ
What is Ginkgo Bioworks (NYSE: DNA) collaborating on with the Gorgas Institute?
What are the specific areas of focus for the collaboration between Ginkgo Bioworks and the Gorgas Institute?
How will the partnership between Ginkgo Bioworks and the Gorgas Institute impact Panama's biosecurity infrastructure?